Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chushifangyi is a traditional Chinese medicine (TCM) prescription developed and used for the prevention of COVID-19. It is administered as a preventive measure in adults, particularly during the COVID-19 pandemic, as part of routine protection strategies. The formulation and specific herbal components are not detailed in the available sources, but it is classified as a TCM intervention rather than a single chemical entity or small molecule drug. Its mechanism of action is presumed to involve immunomodulation and antiviral effects typical of TCM formulas used for respiratory infections, though precise molecular targets are not specified[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chushifangyi.